JPH11513395A - 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト - Google Patents
虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニストInfo
- Publication number
- JPH11513395A JPH11513395A JP9514668A JP51466897A JPH11513395A JP H11513395 A JPH11513395 A JP H11513395A JP 9514668 A JP9514668 A JP 9514668A JP 51466897 A JP51466897 A JP 51466897A JP H11513395 A JPH11513395 A JP H11513395A
- Authority
- JP
- Japan
- Prior art keywords
- ischemic
- kidney
- renal
- treatment
- renal failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.虚血後腎不全の予防および処置並びに虚血腎臓の保護のための医薬組成物 の製造のためのAT1−レセプターアンタゴニストまたは医薬的に許容されるそ の塩の使用。 2.慢性虚血後腎不全の予防および処置のための医薬組成物の製造のための請 求項1に記載の使用。 3.急性虚血後腎不全の予防および処置のための医薬組成物の製造のための請 求項1に記載の使用。 4.血管系または大動脈の手術後、例えば大きな心臓手術後の、対応する手術 の間の腎臓の低還流の場合、血管柄をしばることによる腎臓の意図的な虚血の場 合、腎腫瘍手術、腎動脈手術、腎石手術、腎移植の場合における使用、または腎 臓移植におけるドナーへの予防的な使用、腎毒性問題、細胞外容量枯渇、中程度 の腎還流並びに圧挫症候群により誘導された心不全または腎不全の処置に使用す る医薬組成物の製造のための請求項1に記載の使用。 5.請求項1〜4のいずれか1つに記載の からなる群から選択されたAT1−アンタゴニスト、または各場合における医薬 的に許容されるその塩の使用。 6.請求項1〜4のいずれか1つに記載の式 で示されるバルサルタンまたはその塩の使用。 7.治療有効量のAT1−レセプターアンタゴニストまたは医薬的に許容され るその塩を含有する、虚血後腎不全の予防および処置並びに虚血腎臓の保護のた めの医薬組成物。 8.治療有効量のAT1−レセプターアンタゴニストまたは医薬的に許容され るその塩を投与することを含む、虚血後腎不全の予防および処置並びに虚血腎臓 の保護のための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH2825/95 | 1995-10-06 | ||
CH282595 | 1995-10-06 | ||
PCT/EP1996/004162 WO1997013513A1 (en) | 1995-10-06 | 1996-09-24 | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007258682A Division JP2008019273A (ja) | 1995-10-06 | 2007-10-02 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11513395A true JPH11513395A (ja) | 1999-11-16 |
Family
ID=4242452
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9514668A Withdrawn JPH11513395A (ja) | 1995-10-06 | 1996-09-24 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP2007258682A Ceased JP2008019273A (ja) | 1995-10-06 | 2007-10-02 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP2011176948A Pending JP2011256195A (ja) | 1995-10-06 | 2011-08-12 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007258682A Ceased JP2008019273A (ja) | 1995-10-06 | 2007-10-02 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP2011176948A Pending JP2011256195A (ja) | 1995-10-06 | 2011-08-12 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Country Status (16)
Country | Link |
---|---|
US (1) | US6071931A (ja) |
EP (1) | EP0853477B1 (ja) |
JP (3) | JPH11513395A (ja) |
AT (1) | ATE225657T1 (ja) |
AU (1) | AU7213296A (ja) |
BR (1) | BR9611007A (ja) |
CA (1) | CA2232663C (ja) |
CY (1) | CY2428B1 (ja) |
DE (1) | DE69624253T2 (ja) |
DK (1) | DK0853477T3 (ja) |
ES (1) | ES2184892T3 (ja) |
MY (1) | MY119312A (ja) |
PT (1) | PT853477E (ja) |
TW (1) | TW445147B (ja) |
WO (1) | WO1997013513A1 (ja) |
ZA (1) | ZA968378B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091758A (ja) * | 2000-06-22 | 2007-04-12 | Novartis Ag | 固体バルサルタン医薬組成物 |
JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
IT1295405B1 (it) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
CA2306216C (en) * | 1997-10-17 | 2011-06-07 | Eurogene Limited | The use of inhibitors of the renin-angiotensin system for the treatment of cachexia and wasting |
SI1588706T1 (sl) | 1998-12-23 | 2012-01-31 | Novartis Ag | Tableta valsartana |
SE9902597D0 (sv) * | 1999-07-06 | 1999-07-06 | Astra Ab | New use |
CN1216873C (zh) | 2000-07-19 | 2005-08-31 | 诺瓦提斯公司 | 缬沙坦的盐 |
US20030187038A1 (en) * | 2000-08-25 | 2003-10-02 | Yoshimi Imura | Fibrinogen-lowering agents |
AU2003223637A1 (en) * | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
WO2005097109A1 (en) * | 2004-04-01 | 2005-10-20 | Daniel Batlle | Methods for achieving a protective ace2 expression level |
US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
RU2456615C1 (ru) * | 2011-03-25 | 2012-07-20 | Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации | Способ профилактики отторжения трансплантата трупной почки |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
ATE250587T1 (de) * | 1989-06-14 | 2003-10-15 | Smithkline Beecham Corp | Imidazoalkensäure |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
ATE134624T1 (de) * | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
TW201738B (ja) * | 1990-03-20 | 1993-03-11 | Sanofi Co | |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) * | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5196537A (en) * | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DE69325574T2 (de) * | 1992-04-13 | 2000-03-16 | Zeneca Ltd | ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE |
WO1994005289A1 (en) * | 1992-09-09 | 1994-03-17 | Vanderbilt University | Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation |
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
-
1996
- 1996-09-24 PT PT96933369T patent/PT853477E/pt unknown
- 1996-09-24 MY MYPI96003925A patent/MY119312A/en unknown
- 1996-09-24 ES ES96933369T patent/ES2184892T3/es not_active Expired - Lifetime
- 1996-09-24 US US09/051,345 patent/US6071931A/en not_active Expired - Lifetime
- 1996-09-24 JP JP9514668A patent/JPH11513395A/ja not_active Withdrawn
- 1996-09-24 CA CA002232663A patent/CA2232663C/en not_active Expired - Fee Related
- 1996-09-24 DE DE69624253T patent/DE69624253T2/de not_active Expired - Lifetime
- 1996-09-24 DK DK96933369T patent/DK0853477T3/da active
- 1996-09-24 BR BR9611007A patent/BR9611007A/pt not_active Application Discontinuation
- 1996-09-24 EP EP96933369A patent/EP0853477B1/en not_active Expired - Lifetime
- 1996-09-24 AU AU72132/96A patent/AU7213296A/en not_active Abandoned
- 1996-09-24 WO PCT/EP1996/004162 patent/WO1997013513A1/en active IP Right Grant
- 1996-09-24 AT AT96933369T patent/ATE225657T1/de active
- 1996-09-25 TW TW085111691A patent/TW445147B/zh not_active IP Right Cessation
- 1996-10-04 ZA ZA968378A patent/ZA968378B/xx unknown
-
2004
- 2004-02-27 CY CY0400015A patent/CY2428B1/xx unknown
-
2007
- 2007-10-02 JP JP2007258682A patent/JP2008019273A/ja not_active Ceased
-
2011
- 2011-08-12 JP JP2011176948A patent/JP2011256195A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091758A (ja) * | 2000-06-22 | 2007-04-12 | Novartis Ag | 固体バルサルタン医薬組成物 |
JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2232663A1 (en) | 1997-04-17 |
TW445147B (en) | 2001-07-11 |
EP0853477B1 (en) | 2002-10-09 |
AU7213296A (en) | 1997-04-30 |
ES2184892T3 (es) | 2003-04-16 |
ZA968378B (en) | 1997-04-07 |
US6071931A (en) | 2000-06-06 |
DE69624253T2 (de) | 2003-08-07 |
DE69624253D1 (de) | 2002-11-14 |
PT853477E (pt) | 2003-01-31 |
MY119312A (en) | 2005-05-31 |
EP0853477A1 (en) | 1998-07-22 |
CY2428B1 (en) | 2004-11-12 |
WO1997013513A1 (en) | 1997-04-17 |
ATE225657T1 (de) | 2002-10-15 |
JP2011256195A (ja) | 2011-12-22 |
CA2232663C (en) | 2008-04-08 |
DK0853477T3 (da) | 2003-02-10 |
BR9611007A (pt) | 1999-07-13 |
JP2008019273A (ja) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008019273A (ja) | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト | |
CA2301852C (en) | Angiogenesis promoters and angiogenesis potentiators | |
WO1998002162A1 (fr) | Composes heterocycliques ayant une activite thrombolytique et leur utilisation pour le traitement de la thrombose | |
EP2716302B1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
US20090253665A1 (en) | Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
JPH11503139A (ja) | ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物 | |
AU665694B2 (en) | Angiotension II receptor antagonists for the treatment of disturbances in cardiac rhythm | |
AU2004216133B2 (en) | Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases | |
RU2298405C2 (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
CZ301913B6 (cs) | Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie | |
JP4369994B2 (ja) | アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト | |
JP4836388B2 (ja) | eNOS発現に起因する疾患の予防または治療薬 | |
EP2157089A1 (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
AU715350B2 (en) | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects | |
JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
US20090118334A1 (en) | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker | |
JPH02501655A (ja) | Ace阻害剤の血圧降下作用の増強 | |
WO2003007964A1 (fr) | Remede ou agent preventif de cardiopathie ou d'anevrysme contenant un compose d'inhibition de la chymase | |
Ogiku et al. | No relation of the suppressive effect on the sympathetic nervous system to the acute hypotension caused by imidapril and enalapril | |
JPH06157311A (ja) | 血管病変治療剤 | |
JPWO2003061700A1 (ja) | 慢性腎疾患治療薬 | |
JPWO2003068263A1 (ja) | 高血圧症治療薬 | |
JP2003104894A (ja) | 動脈瘤治療剤または予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070409 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070605 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20071030 |